• 1
    Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:40312.
  • 2
    ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005:106:41325.
  • 3
    Granville CA, Memmott RM, Gills JJ et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006;12:67989.
  • 4
    Maxwell GL, Risinger JI, Tong B et al. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. Gynecol Oncol 1998;70:136.
  • 5
    Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:92430.
  • 6
    Risinger JI, Hayes AK, Berchuck A et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:47368.
  • 7
    Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:35361.
  • 8
    An HJ, Lee YH, Cho NH et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 2002;41:43745.
  • 9
    Erkanli S, Kayaselcuk F, Kuscu E et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer 2006;16:14128.
  • 10
    Zheng W, Baker HE, Mutter GL. Involution of PTEN-null endometrial glands with progestin therapy. Gynecol Oncol 2004;92:100813.
  • 11
    Slomovitz BM, Broaddus RR, Soliman PT et al. mTOR inhibition is a rational target for the treatment of endometrial cancer. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22:5076.
  • 12
    Amezcua CA, Lu JJ, Felix JC et al. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol 2000;79:16976.
  • 13
    Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:12631.
  • 14
    Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:43440.
  • 15
    Horn LC, Schnurrbusch U, Bilek K et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 2004;14:34853.
  • 16
    Wang S, Pudney J, Song J et al. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia—precursor of endometrial cancer. Gynecol Oncol 2003;88:10817.
  • 17
    Yamashita H, Otsuki Y, Matsumoto K et al. Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle. Mol Hum Reprod 1999;5:35864.
  • 18
    Podsypanina K, Lee RT, Politis C et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci U S A 2001;98:103205.
  • 19
    Milam MR, Wu W, Broaddus RR et al. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol 2007;196(3): 247, e1–5.